Article
Use of PNPLA3, TM6SF2, and HSD17B13 for detection of fibrosis in MASLD in the general population.
Clinics and research in hepatology and gastroenterology - 1 Aug 2024
Rashu Elias Badal, Werge Mikkel Parsberg, Hetland Liv Eline, Thing Mira, Nabilou Puria, Kimer Nina, Junker Anders Ellekaer, Jensen Anne-Sofie Houlberg, Nordestgaard Børge Grønne, Stender Stefan, Gluud Lise Lotte
Abstract excerpt
BACKGROUND: Genetic testing can be used to evaluate disease risk. We evaluated if the use of three Single Nucleotide Polymorphisms (SNPs), alone or combined into a genetic risk score (GRS), can aid identify significant fibrosis in subjects with metabolic dysfunction-associated steatotic liver disease (MASLD). METHODS: We assessed three known risk variants: PNPLA3 rs738409, TM6SF2 rs58542926, and HSD17B13...
Read the complete abstract on PubMed